Pancreatic neuroendocrine tumors classified with 2010 WHO classification and 2013 Japanese neuroendocrine tumor guidelines
نویسندگان
چکیده
منابع مشابه
Prognostic factors of non-functioning pancreatic neuroendocrine tumor revisited: The value of WHO 2010 classification
Backgrounds/Aims Various factors have been reported as prognostic factors of non-functional pancreatic neuroendocrine tumors (NF-pNETs). There remains some controversy as to the factors which might actually serve to successfully prognosticate future manifestation and diagnosis of NF-pNETs. As well, consensus regarding management strategy has never been achieved. The aim of this study is to furt...
متن کاملENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.
a Department of Surgery, San Raffaele Hospital, Università Vita e Salute, Milan , Italy; b Department of Endocrine Oncology, University Hospital, Uppsala , Sweden; c Department of Pathophysiology, Division of Endocrinology, National University of Athens, Athens , Greece; d Department of Surgery, Philipps University, Marburg , Germany; e Institute of Oncology (VHIO), Vall d’Hebron University Hos...
متن کاملPancreatic Neuroendocrine Tumors
Pancreatic neuroendocrine tumors are usually indolent (slow-growing) by nature and develop over the course of many years. Pancreatic neuroendocrine tumors are usually more indolent, with better prognosis than adenocarcinoma of the pancreas (Carriaga & Henson, 1995). However, aggressive, fast growing pancreatic neuroendocrine tumors exist and different types of pancreatic neuroendocrine tumors e...
متن کاملUpdate on novel therapies for pancreatic neuroendocrine tumors: 2013.
Neuroendocrine tumors of the pancreas (pNETs) are classified on the basis of their differentiation as well as the functional status. Current treatment options for non resectable disease include everolimus, sunitinib, somatostatin analogs and chemotherapy. A number of trials with novel compounds and drug combinations were reported at the recent ASCO Annual Meeting. Pasireotide is a novel somatos...
متن کاملBiomarkers in pancreatic neuroendocrine tumors.
The aim of biomarkers is to identify patients most likely to benefit from a therapeutic strategy. Pancreatic neuroendocrine tumors are rare neoplasms that arise in the endocrine tissues of the pancreas. Pancreatic neuroendocrine tumors represent 3% of primary pancreatic neoplasms and their incidence has risen. The SMAD4 gene is located on chromosome 18q and someday the SMAD4 gene status may be ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Suizo
سال: 2014
ISSN: 0913-0071,1881-2805
DOI: 10.2958/suizo.29.819